Cannabis and Epilepsy
CBD has strong evidence for rare severe epilepsies; weak evidence for common forms; THC lacks proof.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Pharmaceutical CBD (Epidiolex) genuinely reduces seizures in three rare, severe childhood epilepsy syndromes—Dravet, Lennox-Gastaut, and tuberous sclerosis. For common adult epilepsies, the evidence is much weaker. THC has no solid evidence for seizure control and may actually lower the seizure threshold at high doses. Artisanal CBD products often have wrong labels and unknown contents. This is not a replacement for neurology care.
Not medical advice
This article is informational, not medical advice. Epilepsy is a serious neurological condition. Stopping or changing anti-seizure medication without supervision can trigger status epilepticus, which can be fatal. Do not start, stop, or substitute any treatment—including CBD—based on what you read here. Discuss options with a neurologist or epileptologist, ideally one familiar with cannabinoid pharmacology.
Plain-language summary
Cannabidiol (CBD), one of the major compounds in cannabis, reduces seizures in three rare, severe epilepsy syndromes: Dravet syndrome, Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC) Strong evidence [1][2][3][4]. This reduction is proven by randomized controlled trials and is the basis for FDA approval of the pharmaceutical CBD product Epidiolex [1].
For the much larger population with common adult epilepsies—focal epilepsy, generalized tonic-clonic seizures from other causes, or drug-resistant epilepsy outside the above syndromes—the evidence is thinner. Observational studies and open-label trials report some benefit Weak / limited, but rigorous placebo-controlled trials are limited [5].
THC-dominant cannabis is not an established epilepsy treatment. At high doses, THC has shown both anticonvulsant and pro-convulsant effects in animal models and anecdotal human reports Disputed [8].
CBD carries real medical risks: it raises liver enzymes in approximately 13% of patients, significantly interacts with several anti-seizure medications (notably clobazam and valproate), and causes sedation, diarrhea, and appetite loss Strong evidence [1][5].
What probably works
Pharmaceutical CBD for Dravet syndrome
In a double-blind, placebo-controlled randomized trial, pharmaceutical CBD at 20 mg/kg/day reduced convulsive seizures by a median of 39% compared to 13% reduction on placebo Strong evidence [1]. About 5% of trial participants achieved seizure freedom. CBD was used as an add-on to existing anti-seizure medications, not as a replacement.
Pharmaceutical CBD for Lennox-Gastaut syndrome
Two large randomized trials showed CBD at 10–20 mg/kg/day reduced drop seizures (atonic seizures) by approximately 40–44% versus 17–22% on placebo Strong evidence [2][3]. Again, most participants still experienced seizures after treatment.
Pharmaceutical CBD for tuberous sclerosis complex
A randomized controlled trial demonstrated that CBD reduced TSC-associated seizures significantly more than placebo, leading to FDA approval expansion in 2020 Strong evidence [4].
Key caveats
The effect size, while real, is modest. Most patients remain seizure-free in <10% of cases. CBD works best as an add-on to existing anti-seizure medications; it is not an effective monotherapy replacement in any proven indication. Seizure reduction does not always correlate with improvement in quality of life or neurodevelopmental outcomes, which remain understudied in long-term follow-up.
What might work
CBD for other drug-resistant epilepsies
Expanded access programs and open-label studies in adults and children with mixed, refractory epilepsies have reported median seizure reductions around 36–50% Weak / limited [6]. These studies lack placebo controls. Open-label CBD studies in epilepsy historically show large placebo responses, making it difficult to separate true drug effect from expectation and regression to the mean.
Artisanal and hemp-derived CBD oils
Some families report seizure reduction with whole-plant or hemp-derived CBD products, and the well-publicized "Charlotte's Web" case helped motivate research into pediatric CBD Anecdote. However, product testing repeatedly finds artisanal CBD extracts with inaccurate CBD labels, contamination (heavy metals, pesticides, molds), or unexpected THC content Weak / limited [7]. Any seizure benefit reported in users cannot be confidently attributed to the claimed CBD dose or purity.
CBD for status epilepticus or acute seizures
Limited case series and animal model data exist. CBD is not an established acute seizure treatment and has no role in emergency seizure management Weak / limited.
Whole-plant extract versus isolated pharmaceutical CBD
The "entourage effect"—the idea that cannabis plant compounds work better together than in isolation—is biologically plausible and sometimes cited in observational data [9]. However, no head-to-head randomized trial has shown that whole-plant CBD extract is superior to isolated pharmaceutical CBD for any proven epilepsy indication Weak / limited. Treatment decisions should rely on evidence rather than theoretical mechanisms.
What doesn't work or has weak evidence
THC-dominant cannabis for epilepsy
There is no rigorous controlled human evidence that smoked or vaporized high-THC cannabis controls seizures in any epilepsy population Disputed [8]. Animal studies are mixed: some show anticonvulsant effects, while others—particularly at high doses—demonstrate pro-convulsant activity. Synthetic cannabinoids (K2/Spice) are a documented human seizure trigger [8]. Given this uncertainty and the well-documented harms of acute intoxication and adolescent neurotoxicity, THC is not a standard or recommended epilepsy treatment.
"1:1 CBD:THC ratio is best" for epilepsy
This claim is popular in dispensary marketing; it is not supported by randomized controlled trial evidence for any epilepsy syndrome Anecdote. Consumers may encounter this advice but should recognize it as unsupported folklore.
Specific terpenes (linalool, myrcene, limonene, etc.) as anticonvulsants
Preclinical (animal and cell culture) signals exist for several terpenes Weak / limited. Human clinical evidence is essentially absent No data. Terpene profiles vary widely between cannabis products and over time; marketing claims about "linalool for calm" or "myrcene for seizure control" lack human validation.
What we don't know
- Optimal CBD dose and dosing schedule for drug-resistant epilepsies outside Dravet, LGS, and TSC.
- Long-term safety profile of high-dose daily CBD (>10 years of continuous exposure).
- Whether CBD's seizure benefit arises primarily from a direct anticonvulsant mechanism, from its inhibition of cytochrome P450 enzymes (which raises levels of active metabolites like N-desmethylclobazam), or both [5]. This distinction matters because the drug-interaction-driven portion of efficacy would not generalize to patients not concurrently taking affected medications.
- Whether other cannabinoids—CBDV (cannabidivarin), CBDA (cannabidiolic acid), THCV (tetrahydrocannabivarin)—have meaningful anticonvulsant effects in humans. Preclinical signals are promising; human trials are extremely limited Weak / limited [10].
- Pediatric neurodevelopmental effects of chronic, high-dose CBD during critical brain development windows.
- Optimal CBD formulation (oily suspension vs. powder vs. microemulsion) for absorption and efficacy.
Comparison with standard treatments
First-line epilepsy treatments are anti-seizure medications (ASMs)—including levetiracetam, valproate, lamotrigine, carbamazepine, perampanel, and many others—selected based on seizure type and patient characteristics Strong evidence [11]. Approximately two-thirds of people with newly diagnosed epilepsy achieve good seizure control with a single ASM or combination therapy.
For the remaining one-third with drug-resistant epilepsy (defined as failure of two or more appropriately chosen ASMs), treatment options include trials of further ASMs, ketogenic diet, vagus nerve stimulation, responsive neurostimulation, and epilepsy surgery when appropriate [11].
Pharmaceutical CBD's median seizure-reduction effect size (~40% in Dravet and LGS trials) is comparable to a typical add-on ASM in refractory epilepsy. It is substantially less effective than surgery in surgically remediable epilepsies and has not been directly compared with the ketogenic diet (which shows seizure-free rates of 10–15% in Dravet and LGS in some series).
For children with Dravet, LGS, or TSC who have failed multiple standard ASMs, pharmaceutical CBD is now a guideline-recommended treatment option Strong evidence. For adults with common focal or primary generalized epilepsy, CBD is not standard of care outside clinical trials.
Risks and side effects
From pharmaceutical CBD (Epidiolex)
Randomized trials and post-marketing surveillance data document [1][2][5]:
- Liver enzyme elevations: Approximately 13% of patients show alanine aminotransferase (ALT) elevation ≥3× upper limit of normal; frequency increases when CBD is combined with valproate. Can require dose reduction or discontinuation. Mechanism is unclear; pre-existing hepatic disease or other hepatotoxic drugs may increase risk.
- Sedation and somnolence: Common, particularly when combined with clobazam. Driven partly by CBD's inhibition of CYP2C19, which raises the level of N-desmethylclobazam (a more sedating metabolite) [5].
- Gastrointestinal effects: Diarrhea, decreased appetite, weight loss.
- Drug interactions: Clinically significant interactions documented with clobazam, valproate, warfarin, tacrolimus, everolimus, and CYP3A4 and CYP2C19 substrates. CBD inhibits multiple hepatic cytochrome P450 enzymes, raising levels of co-administered drugs. Consultation with a pharmacist or neurologist familiar with drug interactions is essential.
- Abrupt withdrawal: Discontinuation can trigger increased seizure frequency or status epilepticus; CBD should be tapered gradually under medical supervision.
- Rare adverse effects: Suicidal ideation (in line with other ASMs), hepatotoxicity, and rash have been reported but remain uncommon.
From artisanal CBD products
Uncontrolled products carry additional risks [7]:
- Unknown actual CBD content (often much lower than labeled).
- THC contamination (problematic in children, in individuals with THC sensitivity, and for workplace or drug-testing purposes).
- Heavy metal (lead, cadmium), pesticide (neonicotinoids, organophosphates), and mold (aflatoxins) residues from poorly regulated cultivation and extraction.
- Bacterial or fungal contamination.
From THC-containing cannabis in people with epilepsy
- Acute intoxication and impaired coordination (seizure risk from falls or accidents).
- Possible seizure-threshold lowering or pro-convulsant effects at high doses, particularly in genetically predisposed individuals.
- Concerns about adolescent brain development with regular use and potential impacts on seizure prognosis (understudied).
Sources
- Peer-reviewed Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011–2020.
- Peer-reviewed Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10125):1085–1096.
- Peer-reviewed Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. 2018;378(20):1888–1897.
- Peer-reviewed Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurology. 2021;78(3):285–292.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
- Peer-reviewed Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology. 2016;15(3):270–278.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709.
- Government U.S. National Institute on Drug Abuse. Synthetic Cannabinoids (K2/Spice) DrugFacts. 2020.
- Peer-reviewed Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology. 2018;9:759.
- Peer-reviewed Hill AJ, Mercier MS, Hill TDM, et al. Cannabidivarin is anticonvulsant in mouse and rat. British Journal of Pharmacology. 2012;167(8):1629–1642.
- Peer-reviewed Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–1077.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Cognitive Decline — Evidence on cannabis, memory loss, and dementia risk in adults and older people.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Refractory Epilepsy — Evidence on pharmaceutical CBD for drug-resistant seizures and what remains unproven.
- Cannabis in Pediatric Epilepsy — Pharmaceutical CBD reduces seizures in specific rare pediatric syndromes; retail products...